

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **JBM (Healthcare) Limited**

**健倍苗苗 (保健) 有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2161)**

### **APPOINTMENT OF EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF AUDIT AND NOMINATION COMMITTEES**

The Board announces that with effect from 9 March 2024:

- (a) Dr. Cheng Celine Heung Kwan will be appointed as an executive Director;
- (b) Mr. Yeung Kwok Chun, Harry, a non-executive Director, will be appointed as a member of the Nomination Committee;
- (c) Mr. Chan Kam Chiu, Simon, an independent non-executive Director, will cease to be the chairman of the Audit Committee and will remain a member of the Audit Committee; and
- (d) Mr. Luk Ting Lung, Alan, an independent non-executive Director, will be appointed as the chairman of the Audit Committee.

#### **APPOINTMENT OF EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of JBM (Healthcare) Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Dr. Cheng Celine Heung Kwan (“**Dr. Cheng**”) has been appointed as an executive Director with effect from 9 March 2024.

The biographical details of Dr. Cheng are set out as follows:

Dr. Cheng, aged 62, has around 30 years of experience in sterile and non-sterile manufacturing, quality assurance and Good Manufacturing Practice, specialising in quality management system and reengineering for pharmaceutical and biological products. She currently serves as the Chief Compliance & Technology Officer of Jacobson Pharma Corporation Limited (“**Jacobson**”), a company listed on the Main Board of The Stock Exchange of Hong Kong Limited (Stock Code: 2633) and controlled by Mr. Sum Kwong Yip, Derek, the Chairman of the Board, a non-executive Director and the controlling shareholder of the Company (as defined by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited). Dr. Cheng is primarily responsible for overseeing the quality system integrity, driving technological development and advancing the manufacturing know-how of Jacobson and its subsidiaries.

She earned a Bachelor’s degree in Pharmacy (with honours) and her Ph.D. in pharmacology from the University of Bradford, United Kingdom (“**UK**”) in 1986 and 1990 respectively, and subsequently served as a post-doctoral research fellow at the University of Bradford. She also obtained a Master of Business Administration degree (with distinction) from the City University of Hong Kong in 2006.

Dr. Cheng is a registered pharmacist in both Hong Kong and the UK and is a fellow of the College of Pharmacy Practice of Hong Kong. She is a registered authorised person with the Pharmacy and Poison Board of Hong Kong (the “**PPBHK**”) and served as a member of its various committees. She is currently a member of the Postgraduate Pharmacy Training and Development Committee and the Expert Advisory Group on Bioavailability and Bioequivalence Studies of the PPBHK. She is also a member of the Expert Panel on the Designation of Designated Local Research Institutions at the Innovation and Technology Commission of Hong Kong.

Dr. Cheng has extensive teaching experience. She was an Adjunct Associate Professor at the School of Professional and Continuing Education of the University of Hong Kong from July 2005 to June 2008 and has been an Adjunct Associate Professor at the School of Pharmacy of The Chinese University of Hong Kong since June 2001.

Save as disclosed above and as at the date of this announcement, Dr. Cheng (i) has not previously held and does not hold any other positions with the Group; (ii) did not hold any other directorships in any public companies the securities of which are listed in Hong Kong or overseas in the last three years; and (iii) did not have any other major appointments and professional qualifications.

As at the date of this announcement, save as disclosed above, Dr. Cheng does not have any relationships with any other Directors, senior management, or substantial or controlling shareholders of the Company, and she does not have any interests in the shares or underlying shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Pursuant to a service agreement entered into between Dr. Cheng and the Company, Dr. Cheng is entitled to receive a remuneration of HK\$200,000 per annum (subject to review by the remuneration committee of the Board from time to time). She is also entitled to receive a discretionary bonus as the Board may determine in its absolute discretion from time to time. Such remuneration is determined by reference to factors including her background, qualifications, experiences, duties and responsibilities within the Group, and the prevailing market conditions.

According to the service agreement entered into between Dr. Cheng and the Company, Dr. Cheng shall be appointed for an initial period of three years from the date of appointment. According to the Articles of Association of the Company, Dr. Cheng will hold office until the annual general meeting of the Company in 2024 (the “**2024 AGM**”), and shall then be eligible for re-election at 2024 AGM. Thereafter, she will be subject to retirement by rotation at an annual general meeting of the Company in accordance with the Articles of Association of the Company.

Save as disclosed above, there are no other matters concerning the appointment of Dr. Cheng that need to be brought to the attention of the shareholders of the Company and there is no other information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board would like to express its warmest welcome to Dr. Cheng on her appointment.

## **CHANGE IN COMPOSITION OF AUDIT AND NOMINATION COMMITTEES**

The Board is pleased to announce that the following changes to the nomination committee of the Board (the “**Nomination Committee**”) and the audit committee of the Board (the “**Audit Committee**”) with effect from 9 March 2024:

- (a) Mr. Yeung Kwok Chun, Harry, a non-executive Director, will be appointed as a member of the Nomination Committee;
- (b) Mr. Chan Kam Chiu, Simon, an independent non-executive Director, will cease to be the chairman of the Audit Committee and will remain a member of the Audit Committee; and
- (c) Mr. Luk Ting Lung, Alan, an independent non-executive Director, will be appointed as the chairman of the Audit Committee.

By Order of the Board  
**JBM (Healthcare) Limited**  
**YU Chun Kau**  
*Company Secretary*

Hong Kong, 8 March 2024

*As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek as the Chairman and non-executive Director, Mr. Wong Yat Wai, Patrick (also as Chief Executive Officer) as executive Director, Mr. Yim Chun Leung and Mr. Yeung Kwok Chun, Harry as non-executive Directors, and Mr. Chan Kam Chiu, Simon, Mr. Luk Ting Lung, Alan and Mr. Lau Shut Lee, Tony as independent non-executive Directors.*